**KNEE OSTEOARTHRITIS AND ADVERSE HEALTH OUTCOMES:**

**AN UMBRELLA REVIEW OF META-ANALYSES OF OBSERVATIONAL STUDIES**

Nicola Veronese1,2, Germain Honvo3,4, Olivier Bruyère3,4, René Rizzoli3,5, Mario Barbagallo1, Stefania Maggi6, Lee Smith7, Shaun Sabico2, Nasser Al-Daghri2, Cyrus Cooper8, Francesco Pegreffi9, and Jean-Yves Reginster3,4

**Authors’ Affiliations**:

1 Geriatric Unit, Department of Internal Medicine and Geriatrics, University of Palermo, Palermo, Italy.

2 Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh, Saudi Arabia.

3 World Health Organization (WHO) Collaborating Center for Public Health Aspects of Musculoskeletal Health and Aging, University of Liège, Liège, Belgium

4 Division of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium

5 Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.

6 National Research Council (CNR), Aging Section, Padova, Italy.

7Centre for Health Performance and Wellbeing, Anglia Ruskin University, Cambridge, UK.

8 MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, UK.

9 Department for Life Quality Studies, University of Bologna, Bologna, Italy.

**Corresponding author**:

Nicola Veronese.Geriatric Unit, Department of Internal Medicine and Geriatrics, University of Palermo, via del Vespro, 141, 90127, Palermo, Italy. Phone/fax: 00390916554018. Email: [nicola.veronese@unipa.it](mailto:nicola.veronese@unipa.it)

**ABSTRACT**

**Background:** Knee osteoarthritis (OA) is a common condition, associated with a high rate of disability and poor quality of life. Despite the importance of such evidence in public health, no umbrella review (i.e., a review of other systematic reviews and meta-analyses) has systematically assessed evidence on association between knee OA and adverse health outcomes.

**Aims:** To map and grade all health outcomes associated with knee OA using an umbrella review approach.

**Methods:** The search was made across several databases up to 22nd April 2022. We used an umbrella review of systematic reviews with meta-analyses of observational studies assessing the effect sizes, based on random-effect summary, 95% prediction intervals, heterogeneity, small-study effects, and excess significance bias. The evidence was then graded from convincing (class I) to weak (class IV).

**Results:** Among 3,847 studies initially considered, five meta-analyses were included for a total of five different outcomes. Three adverse outcomes were significantly associated with knee OA (i.e., cardiovascular mortality, falls, and subclinical atherosclerosis). The presence of knee OA was associated with a significantly higher risk of cardiovascular mortality (odds ratio, OR=1.17; 95%CI, confidence intervals: 1.02-1.34), falls (RR=1.34; 95%CI: 1.10-1.64) and conditions associated with subclinical atherosclerosis (OR=1.43; 95%CI: 1.003-2.05). The certainty of each of this evidence was weak.

**Conclusions:** Our umbrella review suggests that knee OA can be considered as putative risk factor for some medical conditions, including cardiovascular diseases and falls, however, it is important to note that the evidence is affected by several potential biases.

**Keywords**: knee osteoarthritis; cardiovascular disease; falls; mortality; meta-analysis; umbrella review.

**INTRODUCTION**

Osteoarthritis (OA) is a common condition, characterized by joint pain and stiffness with relevant consequences on functional status, significantly restricting daily activities, and often resulting in a reduction in quality of life.[[1](#_ENREF_1), [2](#_ENREF_2)] Knee OA is the most common site of OA.[[3](#_ENREF_3)] It is estimated that symptomatic forms may affect more than 250 million people worldwide.[[3](#_ENREF_3)] Moreover, due to extensive structural abnormalities in cellular tissue of cartilage, subchondral bone, synovium, capsule and ligaments leading to pain upon movement and functional limitation, knee OA is ranked among the most common causes of global disability in terms of Disability-Adjusted Life Years (DALY).[[4-7](#_ENREF_4)]

Increasing literature has reported that knee OA could be considered as a potential risk factor for other non-communicable diseases [[8](#_ENREF_8)] such as cardiovascular [[9](#_ENREF_9)] and metabolic conditions [[10](#_ENREF_10), [11](#_ENREF_11)] , as well as mortality. [[8](#_ENREF_8), [12](#_ENREF_12)] Despite the importance of such evidence in public health, to the best of our knowledge, no umbrella review (i.e., a review of other systematic reviews and meta-analyses) has systematically assessed evidence on association between knee OA and related adverse health outcomes (i.e., non-communicable diseases or mortality).

Therefore, the present study addresses the question: What are the adverse health outcomes (i.e., non-communicable diseases or mortality) for which knee OA is a potential risk factor, based on current evidence from systematic reviews of observational studies? The purpose is to highlight the impact of knee OA on patients and health systems, beyond its direct consequences on functional status and quality of life of patients.

**METHODS**

**Protocol and registration**

This study was conducted following the recommendations of the Joanna Briggs Institute (JBI) Collaboration for conducting umbrella reviews [[13](#_ENREF_13)] and those reported in the Cochrane handbook for systematic literature reviews to carry out the screening and selection of studies.[[14](#_ENREF_14), [15](#_ENREF_15)] The protocol is fully available at [https://osf.io/rb9qt/](about:blank). The findings of the umbrella review were reported according to the updated 2020 Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines. [[16](#_ENREF_16)]

**Information sources and search strategies**

For the conduct of this umbrella review, several relevant bibliographic databases were comprehensively searched, including Medline (via Ovid), Embase, Scopus, and CINAHL (Cumulative Index to Nursing and Allied Health Literature) each from inception up to 22nd April 2022.

To guide the identification of adequate key words for building search strategies to search these bibliographic databases, the research question was framed into PICOS (Participants, Intervention, Comparison, Outcome, Study type) format, knowing that there is no intervention in an umbrella review of observational studies. The research question formulated into PICOS format is as follows:

In people with knee OA (P), compared to those without knee OA (C), what are health outcomes (i.e., non-communicable diseases or mortality) associated with knee OA condition (O), based on evidence from systematic reviews with meta-analyses of observational studies(S)?

We built detailed and highly sensitive search strategies combining search terms (free vocabulary words and controlled vocabulary terms) from the main PICOS elements, tailored to the syntax of each of the databases considered for this umbrella review, as shown in **Supplementary Table 1**.

**Eligibility Criteria**

In this umbrella review, we included systematic reviews with formal meta-analyses of observational studies that investigated the relationship between knee OA and any adverse health outcome. Specific inclusion criteria included the following: (1) systematic reviews containing sufficient data for a meta-analysis (as defined by the authors) that assessed knee OA and ascertained health outcomes using self-report (e.g., depression questionnaires), observed (e.g., clinical diagnoses), or objective (e.g., biomarkers and mortality) criteria; and (2) meta-analyses of case-control or cohort studies that investigated the association between knee OA with any adverse health-related outcome (e.g., cardiovascular disease, cancer, death, obesity/overweight, mental illness, diabetes, and metabolic diseases, etc.). Studies had to report these outcomes as odds ratio (OR), relative risk (RR), hazard ratio (HR), or mean and standard deviation or standardized mean differences (for continuous data). We extracted, if available, the estimate adjusted for the highest number of potential confounders. Meta-analyses of cross-sectional studies were excluded from this umbrella review, because in cross-sectional studies, the temporal link between the outcome and the exposure cannot be determined since both are examined at the same time (temporal bias).

**Study selection**

We followed the recommendations in the Cochrane handbook for Systematic reviews to select studies that were finally included in this review.[[15](#_ENREF_15)] The selections were independently carried out by two review authors (SS, FP), with consensus meetings to discuss the studies for which divergent selection decision were made by the two review authors. A third member of the review team (NV) was involved, if necessary. The studies selection process involved, first, a selection based on title and/or abstracts, then a selection of studies retrieved from this first step based on the full-text manuscripts. The Covidence online software ([https://www.covidence.org/](about:blank)) was used to manage the entire study selection process.

**Data collection and data items**

Items collected from the retrieved full-text articles were: Information for identification of the included meta-analyses (e.g., first author name and affiliation, year of publication, journal name, title of the manuscript); data on the characteristics of the population considered, for individual observational studies (e.g., sample size, mean age, location, gender, etc.), as well as data on diagnostic criteria for knee OA (e.g., radiological, clinical, medical records etc.), the study design, the number of cases and controls (or exposed and unexposed), for each individual observational study included in each retrieved systematic review, and health outcomes. These data were collected using a standardized data extraction form. The form was pre-tested by the review authors leading on data extraction. The data extraction was carried out by one review author (SB) and systematically cross checked by a second review author (NV). Errors found in extraction by the second review author were corrected during an online consensus meeting by both authors.

**Assessment of risk of bias**

One author (FP) independently rated the methodological quality of the included systematic reviews using “A MeaSurement Tool to Assess systematic Reviews 2 (AMSTAR 2)”, which ranks the quality of a meta-analysis in one of 4 categories ranging from “critically low” to “high” according to 16 predefined items [[17](#_ENREF_17)], with another author (NV) cross-checking these assessments.

**Data synthesis**

The data analysis was conducted using STATA 14.0. For each meta-analysis, we estimated the common effect size and its 95%CI (confidence interval) through random-effects models.[[18](#_ENREF_18)] We also estimated the prediction interval and its 95% CI, which further accounts for between-study effects and estimates the certainty of the association if a new study addresses that same association.[[19](#_ENREF_19)] Between-study heterogeneity was estimated with the *I*² statistics; values of 50% or greater are indicative of high heterogeneity, while values above 75% suggest very high heterogeneity.[[20](#_ENREF_20)]

In addition, we evaluated the evidence of small-study effects (i.e., whether small studies would have inflated effect sizes compared to larger ones).[[21](#_ENREF_21)] To this end, we used the regression asymmetry test developed by Egger and co-workers.[[22](#_ENREF_22)] A *p* value of less than 0.10 was considered as indicative of small-study effects, whilst a p-value <0.05 of publication bias. Moreover, we considered if the largest study in terms of participants included was statistically significant or not. Finally, we applied Ioannidis's excess of significance test to evaluate whether there was an excess of studies reporting statistically significant results.[[23](#_ENREF_23)]

**Grading the evidence**

Using the tests described in the previous paragraph, we used the credibility assessment criteria, based on established tools for observational evidence.[[24](#_ENREF_24)] We classified the evidence available from meta-analyses of observational studies with nominally statistically significant summary results (*p* < 0.05) into four different categories (Classes I, II, III, and IV). Associations were considered to be convincing (Class I) if they had (1) a statistical significance of *p* value of less than 10–6, (2) included more than 1000 cases (or more than 20,000 participants for continuous outcomes), (3) had the largest component study reporting a significant result (*p* < 0.05), (4) had a 95% prediction interval that excluded the null, (5) did not have large heterogeneity (*I*² < 50%), and (6) showed no evidence of small study effects (*p* > 0.10) or of excess significance bias (*p* > 0.10). Highly suggestive (Class II) evidence was assigned to associations that (1) reported a significance of *p* values of less than 0.001, (2) included more than 1000 cases (or more than 20,000 participants for continuous outcomes), and (3) had the largest component study reporting a statistically significant result (*p* < 0.05). Suggestive (Class III) evidence was assigned to associations that reported a significance of a *p* value of less than 0.01 with more than 1000 cases (or more than 20,000 participants for continuous outcomes). Weak (Class IV) evidence was assigned to the remaining significant associations with a *p* value of less than 0.05.

Due to the inherent limitations of case control studies in examining temporal associations, we plan to provide the classification of evidence for Class I and Class II including only cohort/prospective studies. Outcomes in Class I or Class II were assessed also in terms of possible risk of bias evaluated with the AMSTAR-2. However, since no outcome reached this level of evidence, these analyses were not reported.

**Ethical issues**

This study did not involve patients or any human or animal material, and therefore does not imply any ethical issue.

**RESULTS**

**Literature search**

As shown in **Figure 1**, among 3,847 papers initially considered from databases search, we assessed 40 full-texts. After excluding 36 works (list reported in **Supplementary Table 2**), mainly based on the fact that knee OA was not considered as risk factor for other health outcomes or that wrong criteria for inclusion (e.g., mixed forms of OA instead of knee OA) were used, 4 meta-analyses were included. One additional meta-analysis was identified through manual search of references of the studies included from databases search, so that we finally included five meta-analyses in this umbrella review.[[25-29](#_ENREF_25)]

**Main findings of the umbrella review**

As shown in **Table 1**, the five meta-analyses included a median of 4 studies (range: 3-7) for outcome with a median of 11,071 participants, followed-up for a median of 8 years (range: 7-12). The median of the mean ages from the included studies was 65.1 years, with a median percentage of females of 67.2%. The studies included used different methods for the diagnosis of knee OA, including clinical, radiological or mixed information (**Table 1**).

Among the five outcomes identified from the meta-analyses, the majority considered cardiovascular conditions (incident cardiovascular disease, cardiovascular mortality and conditions associated with subclinical atherosclerosis), together with all-cause mortality and falls. Three adverse outcomes were significantly associated with knee OA (i.e., cardiovascular mortality, falls, and subclinical atherosclerosis), with p-values <0.05. For all the outcomes, except incident cardiovascular diseases, the common effect size was associated with a high heterogeneity (defined as an I2>50%). Small study effect was present in two outcomes (cardiovascular mortality and subclinical atherosclerosis), whilst only subclinical atherosclerosis was associated with the presence of a possible publication bias. Excess significance bias was present for the data regarding cardiovascular mortality. Finally, the largest study in terms of participants showed statistically significant results only in two outcomes (cardiovascular mortality and subclinical atherosclerosis), whilst prediction intervals including the null effect value (i.e., 1.0 for RR or OR) was found for all the outcomes reported (**Table 1**).

Based on the abovementioned criteria, for all the outcomes with statistically significant results, the certainty of evidence was rated as weak. In summary, the presence of knee OA was associated with a significantly higher odds or risk of cardiovascular mortality (OR=1.17; 95%CI: 1.02-1.34), falls (RR=1.34; 95%CI: 1.10-1.64) and conditions associated with subclinical atherosclerosis (OR=1.43; 95%CI: 1.003-2.05) (**Table 1**), but the certainty of each of this evidence was weak.

**Assessment of risk of bias**

Using the criteria suggested by the AMSTAR-2, four meta-analyses were rated as critically low and one low, in terms of methodological quality (**Supplementary Table 3**). The most common reasons of potential bias were “not clear declaration of the PICO question” (question 1), “protocol not published before the work” (question 2), and “missing information regarding the possible role of publication bias in meta-analyses” (question 15).

**DISCUSSION**

In this umbrella review including five systematic reviews with meta-analysis, we found that the presence of knee OA significantly increased the risk of some medical conditions, particularly of cardiovascular nature, and falls. However, it should be noted that these findings were supported by a weak level of evidence, the attempt to identify how knee joint disease influences morbidity and mortality is of paramount importance for public health.

The association between knee OA and cardiovascular diseases, in our case in subclinical forms and cardiovascular mortality, may be explained by several reasons. First, knee OA and cardiovascular diseases have common risk factors such as age and obesity. Moreover, knee OA can increase the risk of traditional risk factors for cardiovascular diseases, i.e., hypercholesterolemia[[30](#_ENREF_30)], hypertension [[31](#_ENREF_31)], aortic calcification[[32](#_ENREF_32)] , lumbar atherosclerotic calcification [[33](#_ENREF_33)] or diabetes.[[34](#_ENREF_34), [35](#_ENREF_35)]. Of importance, a study with a 3 year follow-up reported a strong association between hypertension and impaired glucose tolerance with knee OA occurrence.[[36](#_ENREF_36)] Furthermore, in knee OA patients with hypertension and Type 2 Diabetes Mellitus, greater bone loss in the subchondral plate has been reported, compared with subjects with healthy knee.[[37](#_ENREF_37)] Progressive structural changes in joint morphology results in altered anatomy and consequently in range of motion reduction leading to forced physical inactivity. [[38](#_ENREF_38)] The latter aspect is one of the most recognized risk factors for both cardiovascular disease and mortality.[[38](#_ENREF_38)] Second, it was proposed that people with knee OA may use a greater number of anti-inflammatory drugs, some of them leading to cardiovascular impairment.[[39](#_ENREF_39)] Finally, it is largely known that knee OA may promote sedentary behaviors, mood disorders, and frailty/disability, that can further increase the risk of cardiovascular. [[38](#_ENREF_38)] Other literature has also proposed that changes in extracellular matrix remodeling or altered Wnt signaling transduction, that are present in knee OA, can contribute to subclinical and fatal cardiovascular diseases.[[40](#_ENREF_40), [41](#_ENREF_41)] All these findings suggest that in people with knee OA it is important not only to early detect cardiovascular diseases in sub-clinical forms, but also to strictly monitor those with a high cardiovascular risk.

Another significant result of our umbrella review is that knee OA significantly increased the risk of falls. In addition to the reasons cited before and that can apply to justify this epidemiological association, it is largely known that people with knee OA are prone to postural instability that can increase the risk of falls. [[42](#_ENREF_42)] Functional impairment of the knee joint affected by osteoarthritis and loss of muscle strength lead to a significant increase in the number of falls. Compensatory strategies of patients with knee OA in response to a backward slip perturbation compared with healthy older adults must be considered. In a recent paper comparing healthy older individuals with those who have knee OA patients, it was observed that those with knee OA have a higher risk of falling in response to a backward slip perturbation.[[43](#_ENREF_43)] Moreover, an increase in the number of joints with symptomatic OA of the lower extremities increases the risk of falling.[[44](#_ENREF_44)]

The findings of our study must be interpreted within its limitations. First, the number of meta-analyses included satisfying the selection criteria was limited to only five works with five outcomes, overall indicating the need of more research. Second, the significant associations found between knee OA and health outcomes were affected by some potential biases that ultimately lead to a weak strength of evidence for all these associations. In this sense, we believe that further meta-analyses with larger studies can help overcome these shortcomings. Third, we found a high heterogeneity (as I2 more than 50%) that probably reflects some clinical differences including different definitions of knee OA, follow-up durations, definition of outcomes, and potentially others. Finally, according to the AMSTAR 2 evaluation, the meta-analyses included were rated as critically low or low quality, possibly introducing other biases.

In conclusion, our umbrella review suggests that knee OA can be considered a putative risk factor for some medical conditions, including cardiovascular diseases and falls, however, the evidence was affected by several potential biases and likely mediated by confounders. Since knee OA is the most common musculoskeletal disease, further research is urgently needed for better understanding its epidemiological importance as risk factor for medical conditions.

**ETHICS DECLARATIONS**

**Conflict of interest**: The authors declare no conflict of interest.

**Statement of human and animal rights**: All data used were from published articles, which were following the ethical standards of the institutional review board/international ethics committee for each center and with the 1964 Helsinki Declaration and its later amendments.

**Informed consent**: For this type of study, consent is not required.

**Funding**: The authors extend their appreciation to the Deanship of Scientific Research, King Saud University for funding through Vice Deanship of Scientific Research Chairs.

**REFERENCES**

1. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S (2012) Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. The lancet 380:2197-2223

2. Woolf AD, Pfleger B (2003) Burden of major musculoskeletal conditions. Bulletin of the world health organization 81:646-656

3. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V (2012) Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. The lancet 380:2163-2196

4. Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M, Bridgett L, Williams S, Guillemin F, Hill CL (2014) The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Annals of the rheumatic diseases 73:1323-1330

5. Clynes MA, Jameson KA, Edwards MH, Cooper C, Dennison EM (2019) Impact of osteoarthritis on activities of daily living: does joint site matter? Aging clinical and experimental research 31:1049-1056

6. Salaffi F, Di Carlo M, Carotti M, Farah S, Giovagnoni A (2021) Frailty prevalence according to the Survey of Health, Ageing and Retirement in Europe-Frailty Instrument (SHARE-FI) definition, and its variables associated, in patients with symptomatic knee osteoarthritis: findings from a cross-sectional study. Aging Clinical and Experimental Research 33:1519-1527

7. Jeon H, Lee S-U, Lim J-Y, Chung SG, Lee SJ, Lee SY (2019) Low skeletal muscle mass and radiographic osteoarthritis in knee, hip, and lumbar spine: A cross-sectional study. Aging Clinical and Experimental Research 31:1557-1562

8. Xie H, Ma Y, Shao M, Kong J, Zhou T, Wang F, Cai G, Xu S, Pan F (2021) Telomere length in patients with osteoarthritis: a systematic review and meta-analysis. Aging Clinical and Experimental Research 1-9

9. Hall AJ, Stubbs B, Mamas MA, Myint PK, Smith TO (2016) Association between osteoarthritis and cardiovascular disease: systematic review and meta-analysis. European journal of preventive cardiology 23:938-946

10. Veronese N, Cooper C, Reginster J-Y, Hochberg M, Branco J, Bruyère O, Chapurlat R, Al-Daghri N, Dennison E, Herrero-Beaumont G (2019) Type 2 diabetes mellitus and osteoarthritis. Seminars in arthritis and rheumatism. Elsevier, pp 9-19

11. Yasuda E, Nakamura R, Matsugi R, Goto S, Ikenaga Y, Kuroda K, Nakamura S, Katsuki Y, Katsuki T (2018) Association between the severity of symptomatic knee osteoarthritis and cumulative metabolic factors. Aging clinical and experimental research 30:481-488

12. Hochberg M (2008) Mortality in osteoarthritis. Clinical & Experimental Rheumatology 26:S120

13. Aromataris E, Fernandez R, Godfrey CM, Holly C, Khalil H, Tungpunkom P (2015) Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach. JBI Evidence Implementation 13:132-140

14. Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, Welch V, (editors) (2019) Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons, Chichester (UK),

15. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (2019) Cochrane handbook for systematic reviews of interventions. John Wiley & Sons,

16. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Systematic reviews 10:1-11

17. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, Moher D, Tugwell P, Welch V, Kristjansson E (2017) AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. bmj 358:

18. Geisser S (1974) A predictive approach to the random effect model. Biometrika 61:101-107

19. Nagashima K, Noma H, Furukawa TA (2019) Prediction intervals for random-effects meta-analysis: a confidence distribution approach. Statistical methods in medical research 28:1689-1702

20. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta‐analysis. Statistics in medicine 21:1539-1558

21. Zhang Z, Xu X, Ni H (2013) Small studies may overestimate the effect sizes in critical care meta-analyses: a meta-epidemiological study. Critical Care 17:1-9

22. Harbord RM, Harris RJ, Sterne JA (2009) Updated tests for small-study effects in meta-analyses. The Stata Journal 9:197-210

23. Ioannidis JP, Trikalinos TA (2007) An exploratory test for an excess of significant findings. Clinical trials 4:245-253

24. Papatheodorou SI, Tsilidis KK, Evangelou E, Ioannidis JP (2015) Application of credibility ceilings probes the robustness of meta-analyses of biomarkers and cancer risk. Journal of clinical epidemiology 68:163-174

25. Veronese N, Cereda E, Maggi S, et al. Osteoarthritis and mortality: A prospective cohort study and systematic review with meta-analysis. Seminars in Arthritis and Rheumatism 46:160-167

26. Wang H, Bai J, He B, Hu X, Liu D (2016) Osteoarthritis and the risk of cardiovascular disease: a meta-analysis of observational studies. Sci Rep 6:39672

27. Deng ZH, Xu J, Long LJ, Chen F, Chen K, Lu W, Wang DP, Peng LQ (2021) Association between hip and knee osteoarthritis with falls: A systematic review and meta-analysis. Int J Clin Pract 75:e14537

28. Leyland KM, Gates LS, Sanchez-Santos MT, et al. (2021) Knee osteoarthritis and time-to all-cause mortality in six community-based cohorts: an international meta-analysis of individual participant-level data. Aging Clin Exp Res 33:529-545

29. Macedo MB, Santos V, Pereira RMR, Fuller R (2022) Association between osteoarthritis and atherosclerosis: A systematic review and meta-analysis. Exp Gerontol 161:111734

30. Stürmer T, Sun Y, Sauerland S, Zeissig I, Günther KP, Puhl W, Brenner H (1998) Serum cholesterol and osteoarthritis. The baseline examination of the Ulm Osteoarthritis Study. The Journal of rheumatology 25:1827-1832

31. Veronese N, Stubbs B, Solmi M, Smith TO, Noale M, Schofield P, Maggi S (2018) Knee osteoarthritis and risk of hypertension: a longitudinal cohort study. Rejuvenation research 21:15-21

32. Karasik D, Kiel D, Kiely D, Cupples L, Wilson P, O’Donnell C, Felson D (2006) Abdominal aortic calcification and exostoses at the hand and lumbar spine: the Framingham Study. Calcified tissue international 78:1-8

33. Kurunlahti M, Tervonen O, Vanharanta H, Ilkko E, Suramo I (1999) Association of atherosclerosis with low back pain and the degree of disc degeneration. Spine 24:2080

34. Li X, Zhou Y, Liu J (2022) Association Between Prediabetes and Osteoarthritis: A Meta-Analysis. Hormone and Metabolic Research 54:104-112

35. Veronese N, Cooper C, Reginster JY, et al. (2019) Type 2 diabetes mellitus and osteoarthritis. Seminars in Arthritis and Rheumatism 49:9-19

36. Yoshimura N, Muraki S, Oka H, Tanaka S, Kawaguchi H, Nakamura K, Akune T (2012) Accumulation of metabolic risk factors such as overweight, hypertension, dyslipidaemia, and impaired glucose tolerance raises the risk of occurrence and progression of knee osteoarthritis: a 3-year follow-up of the ROAD study. Osteoarthritis and cartilage 20:1217-1226

37. Wen C, Chen Y, Tang H, Yan C, Lu W, Chiu K (2013) Bone loss at subchondral plate in knee osteoarthritis patients with hypertension and type 2 diabetes mellitus. Osteoarthritis and cartilage 21:1716-1723

38. Veronese N, Trevisan C, De Rui M, Bolzetta F, Maggi S, Zambon S, Musacchio E, Sartori L, Perissinotto E, Crepaldi G (2016) Association of Osteoarthritis with Increased Risk of cardiovascular diseases in the elderly: findings from the Progetto Veneto Anziano study cohort. Arthritis & rheumatology 68:1136-1144

39. Davis A, Robson J (2016) The dangers of NSAIDs: look both ways. British Journal of General Practice, pp 172-173

40. Gay A, Towler DA (2017) Wnt signaling in cardiovascular disease: opportunities and challenges. Current opinion in lipidology 28:387

41. Fan D, Takawale A, Lee J, Kassiri Z (2012) Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis & tissue repair 5:1-13

42. Hsieh R-L, Lee W-C, Lo M-T, Liao W-C (2013) Postural stability in patients with knee osteoarthritis: comparison with controls and evaluation of relationships between postural stability scores and international classification of functioning, disability and health components. Archives of physical medicine and rehabilitation 94:340-346. e341

43. Ren X, Lutter C, Kebbach M, Bruhn S, Yang Q, Bader R, Tischer T (2022) Compensatory responses during slip-induced perturbation in patients with knee osteoarthritis compared with healthy older adults: an increased risk of falls? Frontiers in bioengineering and biotechnology 10:

44. Doré AL, Golightly YM, Mercer VS, Shi XA, Renner JB, Jordan JM, Nelson AE (2015) Lower‐extremity osteoarthritis and the risk of falls in a community‐based longitudinal study of adults with and without osteoarthritis. Arthritis care & research 67:633-639

**Figure 1. PRISMA flow-chart**

**Identification of studies via other methods**

**Identification of studies via databases and registers**

Records identified from:

Citation searching (n = **3**)

Records removed *before screening*:

Duplicate records removed (n = **5408**)

Records identified from:

Ovid Medline (n = **2090**)

Scopus (n = **3367**)

Embase (n = **2632**)

CINAHL (n = **1166**)

**Identification**

Records screened

(n = **3847**)

Records excluded

(n = **3807**)

Reports not retrieved

(n = **0**)

Reports sought for retrieval

(n = **3**)

Reports sought for retrieval

(n = **40**)

Reports not retrieved

(n = 0)

**Screening**

Reports excluded (n = **36**):

Not OA as a risk factor for health outcome(s) (n = **11**)

Wrong Criteria of inclusion (n = **11**)

Wrong outcome (Not health outcome) (n = **7**)

Meta-analysis of cross-sectional studies (n = **2**)

Meta-analysis of RCTs (n = **1**)

Systematic review without Meta-analysis (n = **1**)

Wrong language (n = **1**)

Wrong patient population (n = **1**)

Wrong study design (n = **1**)

Reports assessed for eligibility

(n = **3**)

Reports excluded:

Not knee OA (n = **2**)

Reports assessed for eligibility

(n = **40**)

**Included**

Studies included in review

(n = **5**)

**Table 1. Main findings of the meta-analyses included**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, year** | **Number of studies** | **Sample size** | **Type of studies included** | **Mean age** | **%**  **females** | **Diagnosis of knee OA** | **Outcome** | **Mean follow-up time (years)** | **Type of metric** | **Effect**  **size** | **P-**  **value** | **I2** | **Small study effects** | **Publication bias** | **Excess significance bias** | **Largest study significant** | **Prediction intervals** | **Level of evidence** |
| Veronese, 2016; Leyland, 2021 | 7 | 10320 | Cohort | 62.9 | 69.2 | Clinical + Radiological (3 studies); only radiological (3 studies) | All-cause mortality | 9 | HR | 1.18  (0.95-1.46) | 0.13 | 63.9 | no | no | no | no | 0.64  1.84 | NS |
| Macedo,2022; Wang, 2016 | 4 | 44095 | Cohort | 65.1 | 63 | Clinical (2 studies); radiological (2 studies) | CV  Mortality | 12 | OR | 1.17  (1.02-1.34) | 0.03 | 84.3 | yes | no | yes | yes | 0.68-2.21 | IV |
| Macedo,2022; Wang, 2016 | 3 | 11071 | Cohort | 65.9 | 67.2 | Clinical + Radiological (2 studies); radiological (1 study) | CVD | 8 | HR | 1.09  (0.97-1.24) | 0.16 | 31.2 | no | no | not  possible | no | 0.80-2.15 | NS |
| Deng, 2020 | 4 | 10985 | Cohort | 69.4 | 79.9 | Radiological (3 studies); Clinical + Radiological (1 study) | Falls | 7 | RR | 1.34  (1.10-1.64) | 0.004 | 75.9 | no | no | no | no | 0.84  1.54 | IV |
| Macedo, 2022 | 4 | 11083 | Cohort; case-control | 64.3 | 58 | Radiological (3 studies); clinical (1 study) | Subclinical Atheroclerosis | 8 | OR | 1.43  (1.003-2.05) | 0.043 | 71.5 | yes | yes | not  possible | yes | 0.85-2.84 | IV |

**Abbreviations:** OA: Osteo Arthritis; CV Cardio Vascular; CVD: Cardio Vascular Disease; HR: Hazard Ratio; OR: Odds Ratio; RR: Relative Risk; P-value: Probability value; I2: Index of Heterogeneity; NS: Non Significant.